Table 4

Medium potency estrogen-progestin therapy and risk of ductal and lobular breast cancer stratified by body mass index

Recent BMI

Control group

Ductal cancer

Lobular cancer

Never use

Ever use

Never use

Ever use

Never use

Ever use

No.

No.

No.

OR^a (95%CI)

No.

OR^a (95%CI)

No.

OR^a (95%CI)

No.

OR^a (95%CI)

BMI <22

298

47

126

1.0 (Ref)

49

2.0 (1.2–3.3)

19

1.0 (Ref)

12

3.4 (1.4–8.3)

BMI 22–27

895

132

420

1.1 (0.9–1.4)

114

1.6 (1.1–2.3)

46

0.8 (0.4–1.4)

21

2.2 (1.0–4.6)

BMI >27

514

53

357

1.8 (1.4–2.3)

52

1.9 (1.2–3.1)

56

1.9 (1.1–3.3)

10

2.2 (0.9–5.6)

Exclusive use of medium potency estrogen-progestin therapy, users of more than one kind of menopausal hormone therapy were excluded. Women with unknown age at menopause were excluded. Recent = one year before data collection. ^aAdjusted for age, age at first birth and age at menopause. BMI, body mass index; CI, confidence interval; OR, odds ratio; Ref, reference category.

Rosenberg et al. Breast Cancer Research 2006 8:R11   doi:10.1186/bcr1378